Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)

Taichung Veterans General Hospital-GYNECOLOGY ( Site 0033), Taichung

National Cheng Kung University Hospital-Clinical Trial Center ( Site 0032), Tainan City

St Vincent's Hospital-The Kinghorn Cancer Centre ( Site 0005), Darlinghurst

Royal North Shore Hospital ( Site 0008), St Leonards

Blacktown Hospital ( Site 0003), Sydney

The Alfred Hospital ( Site 0004), Melbourne

Royal Brisbane and Women's Hospital ( Site 0002), Brisbane

Fiona Stanley Hospital ( Site 0006), Murdock

National Taiwan University Hospital ( Site 0031), Taipei

UPMC Hillman Cancer Center ( Site 0644), Pittsburgh

St. Luke's University Health Network ( Site 0636), Bethlehem

Fondazione IRCCS Istituto Nazionale dei Tumori-SC Oncologia Medica 3 - Tumori Testa-collo ( Site 025, Milan

Duke Cancer Institute ( Site 0641), Durham

Centre Hospitalier Régional Universitaire de Brest - Hôpital Morvan ( Site 0154), Brest

Medipol Mega Universite Hastanesi-oncology ( Site 0425), Stanbul

TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 0423), Istanbul

Cleveland Clinic Main ( Site 0639), Cleveland

Universitaetsklinikum Essen ( Site 0185), Essen

Universitaetsklinikum Essen-Klinik für Dermatologie, Venerologie und Allergologie ( Site 0182), Essen

University Malaya Medical Centre ( Site 0061), Lembah Pantai

Institut de cancérologie Strasbourg Europe (ICANS) ( Site 0153), Strasbourg

CENTRE LEON BERARD ( Site 0151), Lyon Cedex08

Hopitaux Universitaires Paris Centre-Hopital Cochin ( Site 0155), Paris

Istituto Nazionale Tumori IRCCS Fondazione Pascale-s.c. melanoma, immunoterapia oncologica e terapi, Napoli

Hospital Sultan Ismail-Pusat Rawatan Radioterapi Dan Onkologi ( Site 0063), Johor Bahru

Sarawak General Hospital-Radiotherapy Unit ( Site 0062), Kuching

Yale-New Haven Hospital-Yale Cancer Center ( Site 0643), New Haven

Dana-Farber Cancer Institute ( Site 0642), Boston

Rutgers Cancer Institute of New Jersey ( Site 0635), New Brunswick

UT Southwestern Medical Center-CRO-Simmons Comprehensive Cancer Center ( Site 0645), Dallas

Sunnybrook Research Institute ( Site 0607), Toronto

Princess Margaret Cancer Centre ( Site 0606), Toronto

Centre Hospitalier de l'Université de Montréal ( Site 0602), Montreal

Jewish General Hospital ( Site 0605), Montreal

McGill University Health Centre ( Site 0604), Montreal

Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0, Québec

Universitaetsklinikum Carl Gustav Carus Dresden-Klinik und Poliklinik für Dermatologie ( Site 0183), Dresden

Radboudumc ( Site 0274), Nijmegen

Erasmus Medisch Centrum ( Site 0272), Rotterdam

University Medical Center Groningen ( Site 0273), Groningen

Gulhane Egitim Arastirma Hastanesi-Onkoloji ( Site 0424), Ankara

Hacettepe Universite Hastaneleri-oncology hospital ( Site 0421), Ankara

Liv Hospital Ankara-Oncology ( Site 0426), Ankara

Ankara Bilkent Şehir Hastanesi ( Site 0427), Ankara